Breakthrough Study Reveals Microglial HMGB1 as Key Driver of Early Brain Inflammation After Stroke
A new research paper published in Experimental Neurology highlights how a specific protein produced by brain immune cells contributes to rapid damage in the minutes and hours following restoration of blood flow after an ischemic stroke. The work focuses on high-mobility group box 1, or HMGB1, released from microglia, the resident immune cells of the central nervous system. By using genetically modified mice lacking this protein specifically in microglia, the team demonstrated significant reductions in early tissue damage and neurological impairment.
The study, appearing in the October 2026 issue of the journal, provides fresh insight into the hyperacute phase of ischemia-reperfusion injury, a period defined here as the first six hours after blood flow returns. This window is critical because many current therapies aim to restore circulation quickly, yet secondary injury processes can still unfold rapidly.
Understanding Cerebral Ischemia-Reperfusion Injury
Ischemic stroke occurs when a blood clot blocks an artery supplying the brain, depriving neurons of oxygen and nutrients. Reperfusion therapies such as clot-dissolving drugs or mechanical clot removal can save lives and limit disability, but the return of blood flow itself can trigger additional harm through oxidative stress, excitotoxicity, disruption of the blood-brain barrier, and intense inflammatory responses. These secondary mechanisms often determine the final extent of brain injury and long-term outcomes.
Global data underscore the scale of the challenge. Stroke ranks as a leading cause of death and long-term disability, with ischemic events comprising the majority of cases. Recent estimates indicate millions of new incidents annually, with substantial impacts on quality of life and healthcare systems worldwide.
The Central Role of Microglia in Early Inflammatory Responses
Microglia constantly survey the brain environment in their resting state, maintaining homeostasis through dynamic processes. Within minutes of ischemic insult, these cells undergo rapid activation, changing shape to an amoeboid form, proliferating, and releasing signaling molecules. This activation can swing toward pro-inflammatory pathways that release cytokines such as tumor necrosis factor alpha and interleukin-6, or toward protective anti-inflammatory states that produce factors like transforming growth factor beta 1.
The balance between these states in the earliest hours after reperfusion heavily influences whether inflammation resolves or escalates into widespread neuronal loss. Upstream signals that initiate this polarization have remained incompletely understood, particularly in the hyperacute timeframe.
HMGB1 as a Damage-Associated Molecular Pattern in Stroke
High-mobility group box 1 normally resides in the cell nucleus, where it helps organize chromatin and regulate gene expression. Under stress from ischemia, it translocates to the cytoplasm and can be released extracellularly, functioning as a damage-associated molecular pattern that alerts the immune system. Once outside the cell, HMGB1 binds receptors including Toll-like receptor 4 and the receptor for advanced glycation end products, sparking inflammatory cascades that recruit additional immune cells and amplify damage.
Prior work has shown elevated HMGB1 levels in both animal models and patients after stroke, with broad inhibition often improving outcomes. However, pinpointing the contribution from specific cell types, especially microglia, has proven difficult because most measurements reflect overall tissue or circulating levels.
Photo by National Cancer Institute on Unsplash
Study Design and Microglia-Specific Genetic Approach
Researchers employed a well-established middle cerebral artery occlusion followed by reperfusion model in adult male mice. They generated conditional knockout animals in which HMGB1 is deleted specifically in microglia through a tamoxifen-inducible Cre recombinase system driven by the Cx3cr1 promoter. Control animals retained normal microglial HMGB1 expression.
Evaluations occurred at the six-hour mark after reperfusion to capture events in the hyperacute phase. Measures included neurological deficit scoring, quantification of ischemic lesion volume via staining techniques, assessment of microglial morphology and activation markers such as ionized calcium-binding adapter molecule 1, expression of pro- and anti-inflammatory cytokines, inducible nitric oxide synthase positive cells, and indicators of neuronal integrity in vulnerable regions including the medial prefrontal cortex and hippocampal CA1 area.
Key Experimental Findings on Lesion Size and Neurological Outcomes
Mice lacking microglial HMGB1 exhibited markedly smaller early ischemic lesion volumes compared with wild-type controls. Acute neurological deficits, assessed through standardized behavioral tests, were also attenuated. These functional improvements aligned with reduced accumulation of activated microglia displaying pro-inflammatory characteristics.
At the molecular level, the knockout animals showed decreased production of pro-inflammatory cytokines TNF-α and IL-6 alongside maintained or elevated levels of the anti-inflammatory mediator TGF-β1. The number of cells co-expressing microglial markers and inducible nitric oxide synthase dropped significantly, indicating a shift away from damaging inflammatory polarization.
Effects on Neuronal Integrity and Inflammatory Marker Profiles
Histological analysis revealed better preservation of neuronal structures in key brain areas in the absence of microglial HMGB1. Wild-type mice displayed pronounced nuclear export of HMGB1 in microglia, amoeboid morphology, and heightened inflammatory signaling within hours. Conditional deletion reshaped these early responses, limiting the amplification loop that drives hyperacute neuroinflammation.
The findings indicate that microglial-derived HMGB1 serves as an important early trigger rather than merely a passive byproduct of injury. Its removal interrupts the cascade at a critical juncture before broader immune cell infiltration and secondary damage cascades fully develop.
Therapeutic Implications and Potential for Targeted Interventions
The results suggest that strategies selectively modulating HMGB1 within microglia could offer precision benefits over systemic blockade, potentially preserving beneficial functions of the protein in other cell types while curbing harmful early inflammation. Such approaches might complement existing reperfusion therapies by extending the effective window or reducing residual deficits.
Further exploration could examine timing of interventions, combination with existing stroke protocols, and translation to larger animal models or human tissue studies. Understanding regional differences in microglial responses across brain areas may also refine therapeutic targeting.
Readers interested in related career opportunities in neuroscience research can explore positions through academic faculty roles or specialized research positions.
Broader Context Within Stroke Research and Future Outlook
This work builds on extensive literature examining damage-associated molecular patterns and microglial dynamics after stroke. It adds cell-type specificity to the understanding of HMGB1, distinguishing its microglial contribution from astrocyte or neuronal sources during the initial hours.
Future studies may investigate longer-term outcomes beyond the hyperacute phase, interactions with peripheral immune cells, and potential biomarkers based on early HMGB1 dynamics. The conditional knockout approach demonstrated here provides a valuable tool for dissecting other microglia-derived mediators in neurological conditions.
For additional background on global stroke burden, consult resources from the World Health Organization. The original publication detailing these experiments is available at ScienceDirect.
Accreditation and Acknowledgments
The research was led by Ke Lei, Siyu Yang, Huoying Chen, Jiapei Dai, Qianjie Tan, Haoyu Wang, E. Du, Jiawei Min, Jiawen Lei, Yi Luo, and Yan Sun. Equal contributions are noted for Ke Lei and Siyu Yang. The study received support from the National Natural Science Foundation of China and related projects, with animal protocols approved by institutional ethics committees following international guidelines.
